secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0000950170-25-063973
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron Therapeutics Q1 2025 net revenue $38.9M, record adj. EBITDA $6.2M, raises FY adj. EBITDA guidance to $4-12M
--------------------------------------------------------------------------------

- Net revenue of $38.9M, up 12.2% YoY; acute care franchise up 89.4% driven by ZYNRELEF (+60.4%).
- Record Q1 adjusted EBITDA of $6.2M; full-year adj. EBITDA guidance raised to $4-12M from $0-8M.
- Settled patent litigation with Mylan on CINVANTI/APONVIE; generic entry agreed for June 1, 2032.
- Cash and investments $50.7M; ZYNRELEF prefilled syringe development on track for early 2027 launch.
- NOPAIN Act took effect April 1; provides separate Medicare payment for non-opioids like ZYNRELEF.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000095017025063973/0000950170-25-063973-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000095017025063973/hrtx-20250506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-063973

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer